

Journal Pre-proof

Comparison of assays measuring extracellular vesicle-tissue factor in plasma samples: Communication from the ISTH SSC Subcommittee on Vascular Biology.

Amandine Bonifay, Nigel Mackman, Yohei Hisada, Ana Teresa Azevedo Sachetto, Chi Hau, Elaine Gray, John Hogwood, Anat Aharon, Lina Badimon, Lucio Barile, Justine Baudar, Lennart Beckmann, Birke Benedikter, Sara Bolis, Tarik Bouriche, Marta Brambilla, Jacopo Burrello, Marina Camera, Elena Campello, Camille Ettelaie, Dorothée Faille, Sophie Featherby, Corentin Franco, Maite Guldenpfennig, John-Bjarne Hansen, Coralie Judicone, Yohan Kim, Soren Risom Kristensen, Katrin Laakmann, Florian Langer, Nadezhda Latysheva, Fabrice Lucien, Erika Marques de Menezes, François Mullier, Philip Norris, Jette Nybo, Josune Orbe, Bjarne Osterud, Jose A. Paramo, Claudia M. Radu, Carmen Roncal, Nazanin Samadi, Omri Snir, Rosa Suades, Casper Wahlund, Corinne Chareyre, Evelyne Abdili, Kimberly Martinod, Johannes Thaler, Françoise Dignat-George, Rienk Nieuwland, Romaric Lacroix

PII: S1538-7836(24)00367-2

DOI: <https://doi.org/10.1016/j.itha.2024.05.037>

Reference: JTHA 690


To appear in: *Journal of Thrombosis and Haemostasis*

Received Date: 29 December 2023

Revised Date: 23 April 2024

Accepted Date: 23 May 2024

Please cite this article as: Bonifay A, Mackman N, Hisada Y, Sachetto ATA, Hau C, Gray E, Hogwood J, Aharon A, Badimon L, Barile L, Baudar J, Beckmann L, Benedikter B, Bolis S, Bouriche T, Brambilla M, Burrello J, Camera M, Campello E, Ettelaie C, Faille D, Featherby S, Franco C, Guldenpfennig M, Hansen J-B, Judicone C, Kim Y, Kristensen SR, Laakmann K, Langer F, Latysheva N, Lucien F, de Menezes EM, Mullier F, Norris P, Nybo J, Orbe J, Osterud B, Paramo JA, Radu CM, Roncal C, Samadi N, Snir O, Suades R, Wahlund C, Chareyre C, Abdili E, Martinod K, Thaler J, Dignat-George F, Nieuwland R, Lacroix R, Comparison of assays measuring extracellular vesicle-tissue factor in plasma samples: Communication from the ISTH SSC Subcommittee on Vascular Biology., *Journal of Thrombosis and Haemostasis* (2024). doi: <https://doi.org/10.1016/j.itha.2024.05.037>.



This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2024 Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.

Comparison of assays measuring extracellular vesicle-tissue factor in plasma samples: Communication from the ISTH SSC Subcommittee on Vascular Biology.

Amandine Bonifay^{*,†}, Nigel Mackman[‡], Yohei Hisada[‡], Ana Teresa Azevedo Sachetto[‡], Chi Hau[§], Elaine Gray[¶], John Hogwood[¶], Anat Aharon^{**,††}, Lina Badimon^{‡‡,§§}, Lucio Barile^{¶¶,***}, Justine Baudar^{†††}, Lennart Beckmann^{‡‡‡}, Birke Benedikter^{§§§,¶¶¶}, Sara Bolis^{¶¶}, Tarik Bouriche^{****}, Marta Brambilla^{††††}, Jacopo Burrello^{¶¶}, Marina Camera^{††††,‡‡‡‡}, Elena Campello^{§§§§}, Camille Ettelaie^{¶¶¶¶}, Dorothée Faille^{*****,†††††}, Sophie Featherby^{¶¶¶¶}, Corentin Franco^{****}, Maite Guldenpfennig^{†††}, John-Bjarne Hansen^{†††††,§§§§§}, Coralie Judicone^{****}, Yohan Kim^{¶¶¶¶¶}, Soren Risom Kristensen^{*****,††††††}, Katrin Laakmann^{§§§}, Florian Langer^{‡‡‡}, Nadezhda Latysheva^{‡‡‡‡}, Fabrice Lucien^{¶¶¶¶¶}, Erika Marques de Menezes^{†††††,§§§§§}, François Mullier^{†††}, Philip Norris^{†††††,§§§§§,¶¶¶¶¶}, Jette Nybo^{*****}, Josune Orbe^{*****,†††††††,‡‡‡‡‡‡}, Bjarne Osterud^{‡‡‡‡}, Jose A. Paramo^{*****,†††††††,¶¶¶¶¶¶¶}, Claudia M. Radu^{§§§§}, Carmen Roncal^{*****,†††††††,‡‡‡‡‡‡,¶¶¶¶¶¶¶}, Nazanin Samadi^{*****}, Omri Snir^{†††††}, Rosa Suades^{‡‡,§§}, Casper Wahlund^{‡‡‡‡}, Corinne Chareyre^{*}, Evelyne Abdili[†], Kimberly Martinod^{††††††††}, Johannes Thaler^{*****}, Françoise Dignat-George^{*,†}, Rienk Nieuwland[§], Romaric Lacroix^{*,†}

* Aix-Marseille University, C2VN, INSERM 1263, INRAE1260, Marseille, France

† Department of Hematology and Vascular Biology, CHU La Conception, APHM, Marseille, France

‡ UNC Blood Research Center, Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

§ Laboratory of Experimental Clinical Chemistry, and Amsterdam Vesicle Center, Amsterdam UMC, location University of Amsterdam, Amsterdam, the Netherlands

¶ National Institute for Biological Standards and Control, Potter's Bar, Hertfordshire, UK

** Hematology Research Laboratory, Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

†† The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

‡‡ Cardiovascular ICCV Program, Research Institute Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, 08025 Barcelona, Spain

§§ Centro de Investigación Biomédica en Red Cardiovascular (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain

¶¶ Cardiovascular Theranostics, Istituto Cardiocentro Ticino, Laboratories for Translational Research, Ente Ospedaliero Cantonale, Bellinzona, Switzerland

*** Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland

††† Université catholique de Louvain, CHU UCL NAMUR, Namur Thrombosis and Hemostasis Center (NTHC), Yvoir, Belgium

- 1 ‡‡‡ Department of Hematology and Oncology, University Cancer Center Hamburg (UCCH), University
- 2 Medical Center Eppendorf, Hamburg, Germany
- 3 §§§ Institute for Lung Research, Universities of Giessen and Marburg Lung Centre, Philipps-University
- 4 Marburg, German Center for Lung Research (DZL), Marburg, Germany
- 5 ¶¶¶ University Eye Clinic Maastricht, MHeNs School for Mental Health and Neuroscience, Maastricht
- 6 University Medical Center + (MUMC+)
- 7 ***** BioCytex, Research and Technology Department, Marseille, France
- 8 †††† Centro Cardiologico Monzino IRCCS, Milan, Italy
- 9 ‡‡‡‡ Department of Pharmaceutical Sciences, Università degli Studi di Milano, Milan, Italy
- 10 §§§§ Department of Medicine, University of Padova, Italy
- 11 ¶¶¶¶ Biomedical Science, University of Hull/HYMS, Cottingham Road, Hull, HU6 7RX, UK
- 12 ***** Université Paris Cité and Université Sorbonne Paris Nord, INSERM, LVTS, F-75018 Paris,
- 13 France
- 14 ††††† Laboratoire d'Hématologie, AP-HP, Hôpital Bichat, F-75018 Paris, France
- 15 ‡‡‡‡‡ Thrombosis Research Group (TREC), Institute of Clinical Medicine, UiT – The Arctic University
- 16 of Norway, Tromsø, Norway
- 17 §§§§§ Thrombosis Research Center (TREC), Division of Internal Medicine, University Hospital of
- 18 North Norway, Tromsø, Norway
- 19 ¶¶¶¶¶ Department of Urology, Department of Immunology, Mayo Clinic, Rochester, MN, USA
- 20 ***** Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark
- 21 †††††† Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
- 22 ‡‡‡‡‡‡ Vitalant Research Institute, San Francisco, CA, USA
- 23 §§§§§§ Department of Laboratory Medicine, University of California, San Francisco, CA, USA
- 24 ¶¶¶¶¶¶ Department of Medicine, UCSF, San Francisco, CA, USA
- 25 ***** Laboratory of Atherothrombosis, Program of Cardiovascular Diseases, Cima Universidad de
- 26 Navarra, Pamplona, Spain
- 27 ††††††† IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain
- 28 ‡‡‡‡‡‡‡ RICORS-Cerebrovascular Diseases, Instituto de Salud Carlos III, Madrid, Spain
- 29 ¶¶¶¶¶¶¶ Centro de Investigación Biomédica en Red Cardiovascular (CIBERCV), Instituto de Salud
- 30 Carlos III, 28029 Madrid, Spain
- 31 ***** Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical
- 32 University of Vienna, Austria
- 33 †††††††† Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, KU
- 34 Leuven, Leuven, Belgium
- 35
- 36

Corresponding author:

Françoise DIGNAT-GEORGE

e-mail address: francoise.dignat-george@univ-amu.fr

Phone number: +33620615478

Abstract

Background

Scientific and clinical interest in extracellular vesicles (EVs) is growing. EVs that expose tissue factor (TF) bind factor VII/VIIa and can trigger coagulation. Highly procoagulant TF-exposing EVs are detectable in the circulation in various diseases, such as sepsis, COVID-19 or cancer. Many in-house and commercially available assays have been developed to measure EV-TF activity and antigen but only a few studies have compared some of these assays. The ISTH SSC Subcommittee on Vascular Biology initiated a multicenter study to compare the sensitivity, specificity and reproducibility of these assays.

Materials and methods

Platelet-depleted plasma samples were prepared from blood of healthy donors. The plasma samples were spiked either with EVs from human milk, or EVs from TF-positive and TF-negative cell lines. Plasma was also prepared from whole human blood with or without LPS stimulation. Twenty-one laboratories measured EV-TF activity and antigen in the prepared samples using their own assays representing 18 functional and 9 antigenic assays.

Results

There was a large variability in the absolute values for the different EV-TF activity and antigen assays. Activity assays had higher specificity and sensitivity compared to antigen assays. In addition, there was a large intra-assay and inter-assay variability. Functional assays that used a blocking anti-TF antibody or immunocapture were the most specific and sensitive. Activity assays that used immunocapture had a lower coefficient of variation compared to assays that isolated EVs by high-speed centrifugation.

Conclusion

Based on this multicenter study, we recommend measuring EV-TF using a functional assay in the presence of an anti-TF antibody.

Keywords

Blood coagulation; Extracellular vesicles; Flow cytometry; Functional assays; Tissue factor

Introduction

Extracellular vesicles (EVs) are a heterogeneous population of submicron membrane vesicles released by cells. EVs are present in biological fluids, such as blood [1], saliva [2], and pleural fluid [3]. They carry proteins, lipids and nucleic acids and are thought to be involved in intercellular communication and pathophysiological processes. Clinical and scientific interest in EVs is growing exponentially. Different subtypes of EVs, such as leukocyte-, endothelial-, or tumor-derived EVs, can trigger coagulation by exposing tissue factor (TF), which binds factor (F) VII/VIIa. Indeed, the TF/FVIIa complex is the main activator of the extrinsic coagulation pathway and thus, leads to fibrin clot formation by activating FIX and FX in the presence of anionic phospholipids [4]. Although TF was initially thought to be exclusively present outside the vasculature ('envelope model'), there is increasing evidence that procoagulant EVs exposing TF (EV-TF) can be present in the circulation in different diseases, such as infectious disorders [5], cancer [6] and coronavirus disease 2019 (COVID-19) [7,8].

Many in-house and commercially available assays have been developed to measure EV-TF [10] but only a few studies have compared different assays [11-15]. These assays have shown promising results for the prediction of venous thromboembolism (VTE) in pancreatic cancer and COVID-19 patients, but further investigations are warranted to prove their clinical utility [6-8].

Therefore, the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee (ISTH SSC) Subcommittee on Vascular Biology initiated a study to compare the analytical performance (sensitivity, specificity and repeatability) of currently available assays to measure TF activity or TF antigen of EVs in human plasma samples.

Materials and methods

Participants

The collaborative project was proposed at the ISTH SSC Congress 2018 (64th annual SSC congress). All interested laboratories that use one or several methods to measure EV-TF were included. Twenty-one laboratories from 13 different countries used 18 functional (activity) and 9 flow cytometry (FCM) assays.

Tested samples

Three types of human plasma samples were prepared by the core laboratories (Supplemental Figure 1). Three sources of EVs were used. First, EVs from the HAP-1 cell line wild-type or KO for TF were employed as a pertinent model to investigate TF specificity of the assays [9]. Indeed, such a strategy allows the generation of EVs with the same composition except for TF, in particular regarding other molecules involved in the EVs procoagulant capacity such as phosphatidylserine. Second, milk-EVs, although not present in blood represent a source of EVs with high level of TF [10]. Third,

lipopolysaccharide (LPS)- and LPS+ EVs samples were used as a source of EVs which mimic healthy donors (LPS-) and inflammatory conditions, such as endotoxemia (LPS+) known to increase TF expression by monocytes and their EVs [11].

Plasma samples spiked with EV-TF and EV-TFKO. EVs were produced from the same cell line, HAP-1 (haploid), and genetically modified by CRISPR Cas9 technology to generate a knockout TF (TFKO) cell line. Parental HAP-1 and TFKO HAP-1 cell lines were purchased from Thermo Fisher Company (Waltham, USA). Cells were maintained in Iscove's Modified Dulbecco Media (IMDM) supplemented with 10% (vol/vol) EV-depleted fetal bovine serum, prepared as recommended by the MISEV guidelines [12], and 1% penicillin/streptavidin. The conditioned culture medium was collected at 48 hours to prepare EVs. EVs were purified by sequential centrifugation steps: $300 \times g$ for 5 minutes followed by $2,500 \times g$ for 10 minutes to remove cells and debris. Then, ultracentrifugation at $100,000 \times g$ for 90 minutes was performed to pellet the EVs, followed by size-exclusion chromatography (SEC) using a qEV original 70 nm column (Izon Science Ltd., Christchurch, New Zealand) to remove soluble proteins. EVs were quantified by flow cytometry (FCM). The gating strategy and acquisition protocol on the CytoFLEX LX (Beckman Coulter, Villepinte, France) instrument were previously described [13]. EVs were defined as annexin-V⁺ and CD59⁺ events. Aliquots of 500 μ L were stored at -80°C . Purified EVs were spiked into EV-depleted plasma (prepared from plasma by centrifugation at $100,000 \times g$ for 90 minutes at 20°C [Blood Bank, Etablissement Français du Sang, Marseille]) to produce low ($1 \times 10^9/\text{L}$) and high ($5 \times 10^9/\text{L}$) levels of EV-TF and EV-TFKO.

Plasma samples spiked with milk EVs. Human breast milk was collected with approval of the Ethics Committee of the Medical University of Vienna (#1721/2015); details on collection, handling and storage have been described previously [10]. Human milk (stored at -80°C) was thawed for one minute at 37°C in a water bath. After thawing, milk was fractionated by SEC using a Sepharose 2B (SEC2B) column as described earlier for plasma [14]. Briefly, 1 mL of milk was fractionated using a qEV original 70 nm column (Izon Science Ltd). Collected fractions were screened using the fibrin generation test (FGT) for their ability to shorten the plasma clotting time in the presence or absence of an anti-TF antibody (TF; clone HTF-1; Thermo Fisher Scientific). As described previously [10], SEC2B fractions 8 and 9 contained the bulk of EVs, and these fractions also contained the highest TF activity. Fractions 8 and 9 were pooled, and from these pooled fractions, a dilution series was generated using the FGT to determine the dilutions that induced shortening of the plasma clotting time comparable to that induced by 142 and 353 fM Innovin (Siemens Healthcare Diagnostics GmbH, Marburg, Germany). To prepare the test samples, the selected dilutions of pooled fractions 8 and 9 were diluted in citrate-anticoagulated EV-poor human pooled plasma. After collection, blood was centrifuged for 5 minutes at $4,190 \times g$, followed by centrifugation of the supernatant for 15 minutes at $3,000 \times g$. The plasma was used in agreement with the guidelines of the Medical Ethical Committee of the Amsterdam Medical Centre,

University of Amsterdam (W19_271#19.421). EV-poor pooled plasma was prepared by centrifugation at $18,890 \times g$ for 60 minutes at 20 °C. Test samples were thawed in the Amsterdam laboratory to validate the stability of EV-TF activity using the FGT before sending out the samples.

Human whole blood samples stimulated by LPS. Negative (LPS-) and positive (LPS+) control plasma samples were prepared as previously described [15]. Briefly, LPS- plasma was prepared using whole blood from healthy volunteers immediately after collection. LPS+ plasma was prepared from whole blood stimulated with LPS (Sigma Aldrich, MO, USA; 10 µg/mL) for 5 hours at 37 °C with agitation. Platelet-depleted plasma (PDP) was prepared by centrifugation of whole blood at $2,500 \times g$ for 15 minutes at room temperature (RT) followed by a second centrifugation at $2,500 \times g$ for 15 minutes at RT as described by the ISTH SSC Collaborative Workshop [16]. PDP was aliquoted and stored at -80 °C.

TF standard for generation of standard curves

TF calibrant (ref: 14/238) was kindly provided by the National Institute for Biological Standards and Control (NIBSC, South Mimms, United Kingdom) [22]. The TF calibrant is made of recombinant TF at the initial concentration of 100U/mL. Participant laboratories were asked to dilute the calibrant 1:4 (25 U/mL) before using it to create an 8-point calibration curve resulting from 1:2 serial dilutions (from 25 to 0.2 U/mL). The purity of the standard was evaluated by Western blotting (anti-TF antibody: cat#AF2339, R&D Systems, Minneapolis, Minnesota, USA) (Supplemental Figure 2). The TF calibrant was used to calibrate functional assays, whatever the principle of TF measurement, to enable comparison using the same units (U/mL).

RT-qPCR

Total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen) according to the manufacturer's recommendations. A two-step RT-qPCR was performed. Total RNA was reverse transcribed into cDNA using the PrimeScript RT Reagent Kit (TaKaRa cat#RR037A). Twenty nanograms of cDNA were amplified in a 20 µL reaction in an MxP3000 instrument (Stratagene, NL) using TaqMan Fast Advanced Master Mix (TaqMan, Applied Biosystems) with predesigned primers for *F3* (Hs00175225_m1) and *RPL13* (Hs00744303_1s) (TaqMan, Applied Biosystems). Each sample was run in duplicate. The relative fold change was determined using the $2^{-\Delta\Delta CT}$ method and normalized to *RPL13A* expression. The absence of TF expression in HAP-1 TFKO cells was confirmed by RT-qPCR (Supplemental Figure 3A).

Western blotting

Western blotting was performed on EVs that were lysed with RIPA buffer. Proteins were separated on a 4-12% NUPAGE gel in the presence of SDS and then transferred onto nitrocellulose membranes (Amersham Protran, Merck Sigma–Aldrich, St Quentin Fallavier, France). Membranes were blocked with 3% bovine serum albumin/tris-buffered saline (TBS, ET220B, Euromedex, Souffelweyersheim, France) for 1 hour at RT. Next, the membranes were incubated overnight at 4 °C with antibodies against integrin $\beta 3$ (1:1000, cat#4702, Cell Signaling Technology, Danvers, Massachusetts, USA), or TF (1:1000, cat#EPR22548-240, Abcam, Cambridge, United Kingdom). Next, horseradish peroxidase (HRP)-conjugated secondary polyclonal antibody (1:2000, Thermo Fisher, cat#31460) was added for 1 hour at RT. Immunocomplexes were detected by enhanced chemiluminescence (ECL substrate) according to the manufacturer's instructions (Pierce, Rockford, IL, USA) and visualized using a G-BOX Imaging System (GeneSys, Cambridge, UK). The absence of TF expression in HAP-1 TFKO cells and EVs was confirmed by western blotting (Supplemental Figure 3B-C).

Measurement of TF activity of wild-type and TFKO HAP-1 cells

A FXa generation assay was performed using HAP-1 wild-type and TFKO cell lines. Briefly, 0.1×10^6 cells in 70 μ L were incubated in hydroxyethyl-piperazineethane-sulfonic acid (HEPES) buffer for 30 minutes at 37 °C with either an inhibitory anti-TF monoclonal antibody (10 μ g/mL final, clone SBTF-1, BioCytex, Marseille, France) or a control antibody (10 μ g/mL, clone a-DNP 2H11–2H12, BioCytex). Next, 7 μ L of HEPES- Ca^{2+} buffer (150 mM NaCl, 20 mM HEPES and 0.1% NaN_3 , 50 mM CaCl_2 , pH 7.4, 0.22 μ m filtrated) containing purified human FVII and FX (Stago BNL, JV Leiden, Netherlands) was added to each sample (final concentrations of 10 nM, 190 nM and 5 mM CaCl_2 , respectively) and incubated for another 2 hours at 37 °C. FXa generation was stopped by the addition of 8 μ L of EDTA buffer (150 mM NaCl, 20 mM HEPES and 0.1% NaN_3 , 200 mM EDTA, pH 7.4, 0.22 μ m filtrated), and a FXa chromogenic substrate (1 mM final, CBS 31.39, Stago) was added. Finally, the color at 390 nm (excitation) and 460 nm (emission) was measured for 15 minutes at 37°C on a microplate reader (Glomax, Promega, Madison, Wisconsin, USA). The maximum reaction velocity (V_{max}) was calculated and corrected by subtracting values generated in the presence of the anti-TF antibody SBTF-1 from those generated in the presence of the control antibody. Data were expressed as femtomolar/L (fM) by comparison to a calibration curve generated using the TF standard. The absence of TF activity in HAP-1 TFKO cells was confirmed by a TF-dependent FXa generation assay (Supplemental Figure 3D).

Study design

Each participating laboratory performed their own assay. A set of 3 aliquots of 8 samples were provided to the participant laboratories (high EV-TF, low EV-TF, high EV-TFKO, low EV-TFKO, high milk-

EV, low milk-EV, LPS+ EVs, and LPS- EVs) (Supplemental Figure 1). All the samples were blinded for the participants and were measured in triplicate using the 3 aliquots provided for each sample. These 8 samples allowed 5 different comparisons to be performed (high EV-TF/high EV-TFKO, low EV-TF/low EV-TFKO, high EV-TFKO/low EV-TFKO, high milk-EV/low milk-EV, and LPS+ EVs/LPS- EVs). TF calibrant was also provided for functional assays. Detailed protocols for storage and thawing of the samples were provided to the participating laboratories. Samples were stored at -80 °C. Before use, samples were quickly thawed at 37°C in a water bath and then incubated at RT for 15 minutes. The participants measured EV-TF in the plasma samples with their own assays (functional and/or antigenic). Raw data and calibrated results were deposited on a secure server using a standardized format.

Analyses of data

Data were analyzed for statistical relevance with GraphPad Prism 8 software (GraphPad Software). Comparisons between 2 groups were performed using a non-parametric test (Mann–Whitney U test) for quantitative variables. The ROUT outlier test was used to identify outliers.

Results

Method characteristics

Twenty-seven assays were included in the study: 18 functional assays and 9 FCM assays. Among the FCM assays, 8 assays were based on a classical principle where EVs are analyzed individually, and one assay analyzed EVs after immunocapture with beads using a commercial assay. The functional assays were divided into 3 assay types: assays measuring the generation of FXa, thrombin, or fibrin. In addition, some functional assays used an anti-TF antibody and the value obtained for the anti-TF antibody condition was subtracted from the value for the isotype control antibody. The detailed characteristics of the functional and FCM assays are described in Supplemental Tables 1 and 2, respectively. These assays were evaluated with regard to their specificity, sensitivity and repeatability.

Specificity of the TF functional assays

To assess the specificity of the functional TF assays, we evaluated their capacity to discriminate between plasma spiked with low or high concentrations of EVs derived from HAP-1 wild-type or TFKO cells. An assay was considered specific when undetectable activity with EV-TFKO samples was observed. Moreover, in order to analyze the specificity among assays which detected an activity with EV-TFKO samples, we calculated the ratio between the high EV-TF and high EV-TFKO samples and the ratio between the low EV-TF and low EV-TFKO samples. We considered that a ratio above 1.2 indicated that the assay was specific for TF based on repeatability analysis (*see below*). The absolute values used to calculate the ratios of each functional assay are shown in Figure 1A-B.

Figure 1A shows that 4/18 (22%) of the assays had an undetectable activity with low EV-TFKO sample and that 12/18 (66%) of the assays had a ratio of above 1.2 for the low EV-TF/low EV-TFKO samples. Assay 7 had a ratio below 1.2 and assay 18 did not measure the EV-TFKO sample. The median ratio for the low EV-TF/low EV-TFKO samples was 10.9 (Table 1). Figure 1B shows that 3/18 (16%) of the assays had an undetectable activity with high EV-TFKO sample and that 14/18 (77%) of the assays had a ratio of above 1.2 using high EV-TF/high EV-TFKO samples. Assay 17 had a ratio below 1.2. The median ratio for the high EV-TF/high EV-TFKO samples was 10.1 (the ROUT outlier test excluded ratios from assays 4 and 13) (Table 1).

Among the FXa generation assays, 9/14 of the assays used either an anti-TF antibody or immunocapture and 5/14 of the assays did not use an anti-TF antibody (Supplemental Table 1). The median ratio for the 6 assays that used an antibody for the low EV-TF/low EV-TFKO was 14.2 compared to 4.6 for the 4 assays that did not use an antibody (a 3.1-fold difference, $p = 0.100$) (Table 1). The median ratio for the 5 assays (the ROUT outlier test excluded assay 4) that used an antibody for the high EV-TF/high EV-TFKO was 23.3 compared to 2.4 for the 4 assays that did not use an antibody (the ROUT outlier test excluded assay 13) (a 9.8-fold difference, $p = 0.015$) (Table 1). For the thrombin generation assays, 2/3 of the assays used an anti-TF antibody (Supplemental Table 1). Similarly, the ratios for the low EV-TF/low EV-TFKO and high EV-TF/high EV-TFKO for the 2 assays that used an antibody were higher than the ratio for these samples for the assays that did not use an antibody (Figure 1).

Taken together, these results show that the use of a blocking antibody against TF or specific immunocapture allows a more specific detection of EV-TF activity using functional assays.

Specificity of the TF antigen assays

To assess the specificity of the FCM TF assays, we evaluated their capacity to discriminate EV-depleted plasma spiked with low or high concentrations of EVs derived from HAP-1 wild-type or TFKO cells. Figures 1C and D show the absolute values for the FCM assays. Only assay B of the 8 classical FCM group had a ratio above 1 (1.2) for the low EV-TF/low EV-TFKO samples. The bead-based FCM used in assay I had a ratio of 8.8. For the high EV-TF/high EV-TFKO samples, assay A had a ratio of 1.5, two assays (E and G) had a ratio of 1.2 or above, 1 assay (B) had a ratio above 1, and 4 assays (C, D, F and H) had a ratio below 1. The bead-based FCM had a ratio of 1.4 for the high EV-TF/high EV-TFKO sample. The high EV-TF/high EV-TFKO samples would be expected to give a greater ratio compared to the low EV-TF/low EV-TFKO samples. However, the bead-based FCM had a higher ratio for the low EV-TF/low EV-TFKO sample compared to the high EV-TF/high EV-TFKO sample. These data suggest that FCM has a low specificity for detecting TF-positive EVs in plasma.

Comparison of the specificity of the TF functional and antigen assays

The median ratio of the TF functional assays for the low EV-TF/low EV-TFKO samples (n=13) was 10.9 compared to 0.5 for the TF antigen assays (classical FCM only, n=8) (a 21.4-fold difference, $p=0.001$) (Table 1). The median ratio of the TF functional assays for the high EV-TF/high EV-TFKO samples (n=13, the ROUT outlier test excluded laboratories 4 and 13) was 10.1 compared to 1.0 for the TF antigen assays (classical FCM only, n=8) (a 10.2-fold difference, $p=0.009$) (Table 1). This indicates that the functional assays are more specific than the antigen assays.

Sensitivity of the TF functional assays

To assess the sensitivity of the TF functional assays, we evaluated the capacity of each assay to discriminate plasma spiked with different concentrations (high and low) of either milk-EVs, EV-TF from a cell line or plasma from healthy donors with or without LPS stimulation (LPS+ and LPS-, respectively). Three ratios were calculated for signals from 1) high and low milk-EV samples, 2) high and low cellular EV-TF samples, and 3) LPS+ and LPS- samples. We considered that a ratio above 1.2 indicates the assay is sensitive for TF. The absolute values used to calculate the ratios of each functional assay are shown in Figure 2A-C.

The median ratios for the high/low milk-EV, high/low cellular EV-TF and LPS+/LPS- samples was 2.2 (n=17), 2.4 (n=16, the ROUT outlier test excluded assay 15) and 6.2 (n=14, the ROUT outlier test excluded assays 6 and 15), respectively (Table 1). For the milk-EV samples, 12/18 (66%) of the assays had a ratio greater than 1.2. Five of the assays had a ratio less than 1.2 and one had a value of 0 for the low milk-EV sample. For the cellular EV-TF samples, 13/18 (72%) of the assays had a ratio greater than 1.2. Four of the assays had a ratio less than 1.2 and one had a value of 0 for the low EV-TF sample. For the LPS+/LPS- samples, 15/18 (83%) of the assays had a ratio greater than 1.2 (Table 1). One of the assays had a ratio less than 1.2 and two had a value of 0 for the LPS- sample.

Among the FXa generation assays, 9/14 of the assays used either an anti-TF antibody or immunocapture and 5/14 did not (Supplemental Table 1). The median ratio for the 9 assays that used an antibody or immunocapture for the milk-EV samples was 2.4 compared to 1.3 for the 5 assays that did not use an antibody or immunocapture (a 1.9-fold difference, $p=0.393$) (Table 1). The median ratio for the 9 assays that used an antibody or immunocapture for the high EV-TF/low EV-TF samples was 2.9 compared to 1.1 for the 5 assays that did not use an antibody or immunocapture (a 2.6-fold difference, $p=0.282$) (Table 1). The median for the 7 assays that used an antibody or immunocapture for the LPS+/LPS- samples (the ROUT outlier test excluded assay 6) was 6.4 compared to 2.5 for the 4 assays that did not use an antibody or immunocapture (a 2.6-fold difference, $p=0.230$) (Table 1). For the thrombin generation assays, 2/3 of the assays used an anti-TF antibody (Supplemental Table 1). Similarly to the FXa generation assays, the ratios for the milk-EV, cellular EV-TF and LPS+/LPS- samples for the 2 assays that used an antibody were higher than the ratios of the assay that did not use

an antibody. These data indicate that the use of an anti-TF antibody or immunocapture increases the sensitivity of the functional assays.

Sensitivity of the TF antigen assays

To assess the sensitivity of the TF antigen assays, we evaluated the capacity of each assay to discriminate plasma spiked with different concentrations (high and low) of either milk-EVs, EV-TF from a cell line or plasma from healthy donors with or without LPS stimulation (LPS+ and LPS-, respectively). The absolute values used to calculate the ratios of each antigen assay are shown in Figure 2D-F.

For the milk-EV samples, the ratio was below 1.2 for all the assays based on classical FCM. The variability of the triplicate measurements can be seen in the Supplemental Figure 4. Laboratories C and D had ratios of 1.10 and 1.05, respectively. The bead-based assay had a ratio of 2.0. For the cellular EV samples, 5/8 (62%) of the assays based on classical FCM had a ratio above 1.2. Two assays had a ratio of 1 and one assay had a ratio of <1. The bead-based assay had a ratio of <1. For the LPS+/LPS- samples, 7/8 (88%) of the assays based on classical FCM had a ratio above 1.2 and one had a ratio <1. The bead-based assay had a ratio of 1.5. These results indicate that some of the antigenic assays could discriminate between the paired samples.

Comparison of the sensitivity of the TF functional and antigen assays

The median ratio of the TF functional assays for the high milk-EV/low milk-EV samples was 2.2 compared to 0.9 for TF antigen assays (classical FCM only) (a 2.4-fold difference, $p=0.016$) (Table 1). The median ratio of the TF functional assays for the high EV-TF/low EV-TF samples (the ROUT outlier test excluded assay 6) was 2.4 compared to 1.1 for the TF antigen assays (classical FCM only) (a 2.6-fold difference, $p=0.007$) (Table 1). The median ratio of the TF functional assays for the LPS+/LPS- samples (the ROUT outlier test excluded assays 6 and 15) was 6.2 compared to 2.2 for TF antigen assays (a 2.80-fold difference, $p=0.016$) (Table 1). This indicates that the functional assays are more sensitive than the antigen assays.

Intra-assay repeatability

To assess the repeatability of functional and FCM assays measuring EV-TF, all samples were measured in triplicate. The coefficient of variation (CV) was calculated for 5 samples: high and low milk-EV, high and low cellular EV-TF, and LPS+ samples.

As shown in Figure 3, a large variability was observed, with CVs ranging from 0.6% to 154% and a median CV of 16% for both functional and antigenic assays. Thus, it was established that a minimum increase of 20% between the EV-KOTF and the EV-TF samples is required to demonstrate

TF specificity in each analysis (ratios above 1.2). Even for the same assay, the repeatability varied significantly between samples (for example, assay 1 varied from 12 to 55%). Interestingly, we observed a higher variability in the TF functional assays isolating EVs by high-speed centrifugation compared to those using immunocapture strategies ($18.4 \pm 15.9\%$, $n=15$, $\text{mean} \pm \text{SD}$ vs. $10.4 \pm 37.2\%$, $n=3$, $\text{mean} \pm \text{SD}$, $p=0.037$).

Taken together, these results indicate the large variability of both functional and antigenic assays measuring TF-positive EVs.

Inter-assay reproducibility

To assess the inter-assay reproducibility, we calculated the inter-assay CV for the 6 functional assays (4 FXa assays, 1 thrombin assay and the fibrin assay) with ratios of specificity and sensitivity above the median (assays 2, 3, 4, 6, 15 and 18) using 5 samples (high milk-EV, low milk-EV, high cellular EV-TF, low cellular EV-TF, and LPS+). The LPS- samples were not used because the activity measured was too low and close to the detection threshold of the assays. As shown in Figure 4, despite the use of a common calibrant, the inter-assay reproducibility ranged from 88 to 134% according to the sample, highlighting a lack of inter-assay reproducibility.

Discussion

Multiple assays are used in the literature to measure EV-TF [17]. Major concerns include the specificity, sensitivity, and repeatability of these assays to ensure robust and reproducible data between laboratories. This multicenter study compared the analytical performances of 27 EV-TF assays performed by expert laboratories. The main findings of the study are that functional assays using a blocking anti-TF antibody or specific immunocapture were most sensitive and specific compared to functional assays that did not use an anti-TF antibody, activity assays are more sensitive and specific compared to antigen assays, there was lower variability using immunocapture compared to isolation of EVs using centrifugation and there was a high variability between the different assays.

Previous monocentric studies have compared functional assays [11-15]. Two studies compared in-house FXa and thrombin generation assays to a TF immunocapture commercialized assay and reported a lower specificity and sensitivity of the TF immunocapture commercialized assay than the in-house assays [18,19]. Another study comparing two FXa generation assays improved the sensitivity by using FVII instead of FVIIa and the clone SBTF1 as a TF-blocking antibody instead of HTF-1 [20]. Recently, a study compared the thrombin generation assay published by Osterud *et al.* [9] to the FXa generation assay developed by the Mackman team. It showed that these two assays allow measurement of EV-TF in a specific and reproducible manner [21].

Our collaborative multicenter study is the first to compare 18 functional assays with different principles (FXa, FIIa or fibrin generation assays) performed by 16 expert laboratories. We observed that functional assays displayed variable performances in terms of specificity and sensitivity. The main demonstration of this collaborative study is that the use of an antibody that inhibits TF activity increased the specificity and sensitivity of the assays. This conclusion strengthens the recommendation of expert opinion to use a TF blocking antibody [22,23]. Moreover, it is consistent with the demonstration that TF-independent activity can be caused by 1) the presence of phospholipids in a concentration-dependent manner [20] and 2) the use of FVIIa instead of FVII [20] because FVIIa can activate FX in a concentration-dependent manner independent of TF [24]. The Zymuphen MP-TF immunocapture assay (assays 8 and 9) displayed a lack of sensitivity to discriminate low and high milk-EV samples compared to the FXa generation assays that used a TF-blocking antibody. This could be explained, in part, by a failure of the immunocapture of these EVs purified from milk. Furthermore, in the current study, the sensitivity of the assays was evaluated as the discriminative capacity to differentiate two levels of EVs. Therefore, the study did not allow for determination of the limit of detection or the ability to detect an activity in healthy samples, which will require further evaluation.

The 8 classical FCM assays were less specific and sensitive compared to the functional assays. Only 1/8 of the assays had a ratio >1.2 for the low EV-TF/low EV-TFKO samples whereas 50% of the assays had a ratio >1.0 (1.06-1.52) for the high EV-TF/high EV-TFKO samples. Additionally, 7/8 of the FCM assays show a ratio >1 for high EV-TF/low EV-TF and LPS+/- samples. The functional assays showed that the 3 different paired samples had a range of sensitivities between the high and low samples in the following order: LPS+/LPS- samples $>$ cellular EV samples $>$ milk-EV samples. Interestingly, the median ratios for the FCM assays for the LPS+/-, cellular EV and milk-EV samples were 2.21, 1.61 and 0.91, respectively. Altogether, these data suggest a trend towards detecting TF+ EVs in plasma which may be due to a variation of the TF antigen density on the surface of EVs between those produced after LPS stimulation of whole blood and those spiked into plasma.

These issues in terms of specificity and sensitivity of FCM are in line with a large range of values reported in healthy donors, from less than ten to several thousand TF+ EVs per microliter in plasmatic samples [25–28]. The sensitivity of EV-TF measurement by FCM is reduced for several reasons. First, EVs are small (most have a diameter near 100-150 nm) and consequently have a low antigen density, exposing at best only a few TF molecules. Even when an antibody can label all TF molecules on a single EV, the fluorescence signal may be below the limit of detection of a FCM fluorescence detector. Here the accurate identification of EV through FCM analysis primarily relies on the performances of the instrument used in the analysis. Second, TF could be masked for antibody labeling by FVII(a) binding to TF or by coverage of TF+ EVs by a fibrin cap [29]. This hypothesis is supported since 1) FVII/FVIIa has a very high affinity for TF, and 2) EV-TF activity was compared with or without exogenous FVIIa and significant levels were observed in the absence of exogenous FVIIa-

TF activity after addition of an TFPI antibody was found suggesting that TFPI is bound to the TF/FVII complex. However, it should be noted that the most used anti-TF monoclonal antibody (HTF-1 clone) used to block TF competes with FVII/FVIIa for binding to TF. This means that anti-TF antibodies used for FCM can displace bound FVII/FVIIa from TF. In addition to these issues impacting sensitivity, another major limitation is FCM specificity. The misuse of isotype control antibodies in FCM experiments may lead to the detection of false-positive events [30,31]. Consequently, the events thought to be TF+ EVs are sometimes correlated with the total number of EVs in the sample and therefore may just reflect the increase in total EVs in diseases [32,33]. This could explain some of the difference in EV-TF quantification between LPS- and LPS+ samples in our study. However, in a recent study LPS stimulation of whole human blood didn't increase the levels of EVs isolated using a 20,000 g spin [35]. In sum, the current limitations of FCM analytic performances and associated reagents mean that it is difficult to reliably measure TF carried by EVs in biological samples using FCM. FCM has already benefited from tremendous developments over the past decade to improve its sensitivity to measure EVs with a positive impact in many applications [33]. It is likely that future developments may change the conclusion of the present study.

The ratios from the bead-based FCM from the different samples are difficult to interpret. The ratio for the high EV-TF/high EV-TFKO sample (1.41) is lower than the ratio for the low EV-TF/low EV-TFKO sample (8.76). The ratios for the milk-EV, cellular EV samples and the LPS+/LPS-sample were 2.01, 0.35 and 1.52, respectively. A recent study concluded that the bead-based FCM kit did not have the sensitivity to detect TF-positive EVs in plasma [15].

Both intra and inter-assay reproducibility show a huge heterogeneity of the results. First, most of the functional assays displayed a CV below 20%, but their repeatability was inconsistent and lacked robustness. Indeed, within the same assay, CVs ranging from 2% to 112% were observed (assay 12). Inter-assay reproducibility also showed a large variability of the absolute values between assays using a common calibrant.

Several reasons can explain this variability. The preanalytical step has been identified as one of the major sources of variability in the EV measurement. Previous studies have identified the delay before the first centrifugation, the agitation of the tubes during transportation and the centrifugation step as the most critical parameters [16]. In this study, we can rule out the impact of the time delay and the transportation because similar aliquots already prepared by core labs were sent to the participant laboratories. Thus, the centrifugation remains the most probable cause of the intra-assay variability. Previous studies show that the recovery of the pellet depends on the rotor type, the centrifugation speed (g-force), the temperature, the use of brake [34] and the centrifugation time and limits the repeatability of EV measurement [20,35]. Another source of variability may be the detection step (i.e. the equipment used, time and agitation) but the use of a common calibrant in the study should have prevented a

significant impact of these variables between assays. An additional cause of the inter-assay variability may be the manual aspect of the EV-TF assays which may contain some steps with high risk of EV loss.

The future directions for improving the variability of results are based on three potential strategies, which are not exclusive: first, standardization of reagents and homogenization of protocols which emerge from the assays having presented the best analytical performances in terms of sensitivity and specificity. Secondly, proposing a pre-analytical step independent of centrifugation, which is the most important cause of variability, as was recently published with the preparation of EVs by magnetic immunoseparation [36], and thirdly, moving to an automated version of these assays.

This study represents a first step towards a better selection of the most appropriate methods to measure EV-TF, but cannot be considered as a standardization study. Indeed, flow cytometry assays do not benefit from a common standardization tool, and the calibrant used to compare functional assays (recombinant soluble TF) has by nature significant differences from EV-TF. Moreover, the initial choice of the calibration curve range resulted in some extrapolated values for 6/18 functional assays. However, further methodological and standardization efforts are mandatory before considering EV-TF as a biomarker in clinical practice to predict thrombosis in patients at high risk, such as those with cancer or thromboinflammatory diseases.

Author contributions

F.D.-G., N.M., R.L. and R.N. conceived and design the analysis, A.B. collected the data, A.B., A.T.A.S., F.D.-G., N.M., R.L., R.N. and Y.H. analyzed, interpreted the data and wrote the paper, F.D.-G. and R.L. supervised the work. All authors contributed data, critically contributed to the revised version of the manuscript for important intellectual content and gave final approval for the version to be published.

Acknowledgements

This study received funding from an ISTH SSC Small Project grant to R.L. The authors thank the co-chairs of the Vascular Biology Subcommittee for reviewing and commenting on the manuscript.

Conflicts of interest

F.D.-G. and R.L. filed a patent on microvesicles fibrinolytic activity licensed to Stago and obtained a common grant within the framework of the excellence program INNOV-CKD.

The remaining authors declare no competing financial interests.

References

1. Pang B, Zhu Y, Ni J, Thompson J, Malouf D, Bucci J, Graham P, Li Y. Extracellular vesicles: the next generation of biomarkers for liquid biopsy-based prostate cancer diagnosis. *Theranostics*. 2020 Jan 16;10(5):2309–26.
2. Berckmans RJ, Sturk A, van Tienen LM, Schaap MCL, Nieuwland R. Cell-derived vesicles exposing coagulant tissue factor in saliva. *Blood*. 2011 Mar 17;117(11):3172–80.
3. Roca E, Lacroix R, Judicone C, Laroumagne S, Robert S, Cointe S, Muller A, Kaspi E, Roll P, Brisson AR, Tantucci C, Astoul P, Dignat-George F. Detection of EpCAM-positive microparticles in pleural fluid: A new approach to mini-invasively identify patients with malignant pleural effusions. *Oncotarget*. 2016 Jan 19;7(3):3357–66.
4. Grover SP, Mackman N. Tissue Factor: An Essential Mediator of Hemostasis and Trigger of Thrombosis. *Arterioscler Thromb Vasc Biol*. 2018 Apr;38(4):709–25.
5. Rondina MT, Tatsumi K, Bastarache JA, Mackman N. Microvesicle Tissue Factor Activity and IL-8 Levels are Associated with Mortality in Patients with Influenza A/H1N1 Infection. *Crit Care Med*. 2016 Jul;44(7):e574–8.
6. Lacroix R, Vallier L, Bonifay A, Simoncini S, Mege D, Aubert M, Panicot-Dubois L, Dubois C, Dignat-George F. Microvesicles and Cancer Associated Thrombosis. *Semin Thromb Hemost*. 2019 Sep;45(6):593–603.
7. Guervilly C, Bonifay A, Burtey S, Sabatier F, Cauchois R, Abdili E, Arnaud L, Lano G, Pietri L, Robert T, Velier M, Papazian L, Albanese J, Kaplanski G, Dignat-George F, Lacroix R. Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19. *Blood Advances*. 2021 Jan 29;5(3):628–34.
8. Rosell A, Havervall S, von Meijenföldt F, Hisada Y, Aguilera K, Grover SP, Lisman T, Mackman N, Thålin C. Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortality. *Arterioscler Thromb Vasc Biol*. 2020 Dec 3;ATVBAHA120315547.
9. Østerud B, Latysheva N, Schoergenhofer C, Jilma B, Hansen JB, Snir O. A rapid, sensitive, and specific assay to measure TF activity based on chromogenic determination of thrombin generation. *J Thromb Haemost*. 2022 Apr;20(4):866–76.
10. Hu Y, Hell L, Kendlbacher RA, Hajji N, Hau C, van Dam A, Berckmans RJ, Wisgrill L, Ay C, Pabinger I, Brisson A, Repa A, Nieuwland R, Thaler J. Human milk triggers coagulation via tissue factor-exposing extracellular vesicles. *Blood Adv*. 2020 Dec 22;4(24):6274–82.
11. Sachetto ATA, Mackman N. Monocyte tissue factor expression: LPS induction and roles in pathological activation of coagulation. *Thromb Haemost*. 2023 May 11;
12. Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, Antoniou A, Arab T, Archer F, Atkin-Smith GK, Ayre DC, Bach JM, Bachurski D, Baharvand H, Balaj L, Baldacchino S, Bauer NN, Baxter AA, Bebawy M, Beckham C, Bedina Zavec A, Benmoussa A, Berardi AC, Bergese P, Bielska E, Blenkiron C, Bobis-Wozowicz S, Boilard E, Boireau W, Bongiovanni A, Borràs FE, Bosch S, Boulanger CM, Breakefield X, Breglio AM, Brennan MA, Brigstock DR, Brisson A, Broekman ML, Bromberg JF, Bryl-Górecka P, Buch S, Buck AH, Burger D, Busatto S, Buschmann D, Bussolati B, Buzás EI, Byrd JB, Camussi G, Carter DR, Caruso S, Chamley LW, Chang YT, Chen C, Chen S, Cheng L, Chin AR, Clayton A, Clerici SP, Cocks A, Cocucci E, Coffey RJ, Cordeiro-da-Silva A, Couch Y, Coumans FA, Coyle B, Crescitelli

- R, Criado MF, D'Souza-Schorey C, Das S, Datta Chaudhuri A, de Candia P, De Santana EF, De Wever O, Del Portillo HA, Demaret T, Deville S, Devitt A, Dhondt B, Di Vizio D, Dieterich LC, Dolo V, Dominguez Rubio AP, Dominici M, Dourado MR, Driedonks TA, Duarte FV, Duncan HM, Eichenberger RM, Ekström K, El Andaloussi S, Elie-Caille C, Erdbrügger U, Falcón-Pérez JM, Fatima F, Fish JE, Flores-Bellver M, Försonits A, Frelet-Barrand A, Fricke F, Fuhrmann G, Gabrielsson S, Gámez-Valero A, Gardiner C, Gärtner K, Gaudin R, Gho YS, Giebel B, Gilbert C, Gimona M, Giusti I, Goberdhan DC, Görgens A, Gorski SM, Greening DW, Gross JC, Gualerzi A, Gupta GN, Gustafson D, Handberg A, Haraszti RA, Harrison P, Hegyesi H, Hendrix A, Hill AF, Hochberg FH, Hoffmann KF, Holder B, Holthofer H, Hosseinkhani B, Hu G, Huang Y, Huber V, Hunt S, Ibrahim AGE, Ikezu T, Inal JM, Isin M, Ivanova A, Jackson HK, Jacobsen S, Jay SM, Jayachandran M, Jenster G, Jiang L, Johnson SM, Jones JC, Jong A, Jovanovic-Talisman T, Jung S, Kalluri R, Kano SI, Kaur S, Kawamura Y, Keller ET, Khamari D, Khomyakova E, Khvorova A, Kierulf P, Kim KP, Kislinger T, Klingeborn M, Klink DJ, Kornek M, Kosanović MM, Kovács ÁF, Krämer-Albers EM, Krasemann S, Krause M, Kurochkin IV, Kusuma GD, Kuypers S, Laitinen S, Langevin SM, Languino LR, Lannigan J, Lässer C, Laurent LC, Lavieu G, Lázaro-Ibáñez E, Le Lay S, Lee MS, Lee YXF, Lemos DS, Lenassi M, Leszczynska A, Li IT, Liao K, Libregts SF, Ligeti E, Lim R, Lim SK, Linē A, Linnemannstons K, Llorente A, Lombard CA, Lorenowicz MJ, Lörincz ÁM, Lötvall J, Lovett J, Lowry MC, Loyer X, Lu Q, Lukomska B, Lunavat TR, Maas SL, Malhi H, Marcilla A, Mariani J, Mariscal J, Martens-Uzunova ES, Martin-Jaular L, Martinez MC, Martins VR, Mathieu M, Mathivanan S, Maugeri M, McGinnis LK, McVey MJ, Meckes DG, Meehan KL, Mertens I, Minciacchi VR, Möller A, Møller Jørgensen M, Morales-Kastresana A, Morhayim J, Mullier F, Muraca M, Musante L, Mussack V, Muth DC, Myburgh KH, Najrana T, Nawaz M, Nazarenko I, Nejsun P, Neri C, Neri T, Nieuwland R, Nimrichter L, Nolan JP, Nolte-'t Hoen EN, Noren Hooten N, O'Driscoll L, O'Grady T, O'Loughlen A, Ochiya T, Olivier M, Ortiz A, Ortiz LA, Osteikoetxea X, Østergaard O, Ostrowski M, Park J, Pegtel DM, Peinado H, Perut F, Pfaffl MW, Phinney DG, Pieters BC, Pink RC, Pisetsky DS, Pogge von Strandmann E, Polakovicova I, Poon IK, Powell BH, Prada I, Pulliam L, Quesenberry P, Radeghieri A, Raffai RL, Raimondo S, Rak J, Ramirez MI, Raposo G, Rayyan MS, Regev-Rudzki N, Ricklefs FL, Robbins PD, Roberts DD, Rodrigues SC, Rohde E, Rome S, Rouschop KM, Ruggetti A, Russell AE, Saá P, Sahoo S, Salas-Huenuleo E, Sánchez C, Saugstad JA, Saul MJ, Schiffelers RM, Schneider R, Schøyen TH, Scott A, Shahaj E, Sharma S, Shatnyeva O, Shekari F, Shelke GV, Shetty AK, Shiba K, Siljander PRM, Silva AM, Skowronek A, Snyder OL, Soares RP, Sódar BW, Soekmadji C, Sotillo J, Stahl PD, Stoorvogel W, Stott SL, Strasser EF, Swift S, Tahara H, Tewari M, Timms K, Tiwari S, Tixeira R, Tkach M, Toh WS, Tomasini R, Torrecilhas AC, Tosar JP, Toxavidis V, Urbanelli L, Vader P, van Balkom BW, van der Grein SG, Van Deun J, van Herwijnen MJ, Van Keuren-Jensen K, van Niel G, van Royen ME, van Wijnen AJ, Vasconcelos MH, Vechetti IJ, Veit TD, Vella LJ, Velot É, Verweij FJ, Vestad B, Viñas JL, Visnovitz T, Vukman KV, Wahlgren J, Watson DC, Wauben MH, Weaver A, Webber JP, Weber V, Wehman AM, Weiss DJ, Welsh JA, Wendt S, Wheelock AM, Wiener Z, Witte L, Wolfram J, Xagorari A, Xander P, Xu J, Yan X, Yáñez-Mó M, Yin H, Yuana Y, Zappulli V, Zarubova J, Žekas V, Zhang JY, Zhao Z, Zheng L, Zheutlin AR, Zickler AM, Zimmermann P, Zivkovic AM, Zocco D, Zuba-Surma EK. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *J Extracell Vesicles*. 2018;7(1):1535750.
13. Bonifay A, Robert S, Champagne B, Petit PR, Eugène A, Chareyre C, Duchez AC, Véliér M, Fritz S, Vallier L, Lacroix R, Dignat-George F. A new strategy to count and sort neutrophil-derived extracellular vesicles: Validation in infectious disorders. *J Extracell Vesicles*. 2022 Apr;11(4):e12204.
14. Böing AN, Pol E van der, Grootemaat AE, Coumans FAW, Sturk A, Nieuwland R. Single-step isolation of extracellular vesicles by size-exclusion chromatography. *Journal of Extracellular Vesicles*. 2014 Jan 1;3(1):23430.

- 1 15. Hisada Y, Mackman N. Measurement of tissue factor activity in extracellular vesicles from human
2 plasma samples. *Res Pract Thromb Haemost*. 2019 Jan;3(1):44–8.
- 3 16. Lacroix R, Judicone C, Poncelet P, Robert S, Arnaud L, Sampol J, Dignat-George F. Impact of
4 pre-analytical parameters on the measurement of circulating microparticles: towards
5 standardization of protocol. *J Thromb Haemost*. 2012 Mar;10(3):437–46.
- 6 17. Mackman N, Sachetto ATA, Hisada Y. Measurement of tissue factor-positive extracellular
7 vesicles in plasma: strengths and weaknesses of current methods. *Curr Opin Hematol*. 2022 Sep
8 1;29(5):266–74.
- 9 18. Hellum M, Øvstebø R, Trøseid AMS, Berg JP, Brandtzaeg P, Henriksson CE. Microparticle-
10 associated tissue factor activity measured with the Zymuphen MP-TF kit and the calibrated
11 automated thrombogram assay. *Blood Coagul Fibrinolysis*. 2012 Sep;23(6):520–6.
- 12 19. Tatsumi K, Antoniak S, Monroe DM, Khorana AA, Mackman N, Subcommittee on Hemostasis
13 and Malignancy of the Scientific and Standardization Committee of the International Society on
14 Thrombosis and Hemostasis. Evaluation of a new commercial assay to measure microparticle
15 tissue factor activity in plasma: communication from the SSC of the ISTH. *J Thromb Haemost*.
16 2014 Nov;12(11):1932–4.
- 17 20. Vallier L, Bouriche T, Bonifay A, Judicone C, Bez J, Franco C, Guervilly C, Hisada Y, Mackman
18 N, Houston R, Poncelet P, Dignat-George F, Lacroix R. Increasing the sensitivity of the human
19 microvesicle tissue factor activity assay. *Thromb Res*. 2019 Oct;182:64–74.
- 20 21. Tanratana P, Azevedo Sachetto AT, Mackman N. ‘A rapid, sensitive, and specific assay to measure
21 tissue factor activity based on chromogenic determination of thrombin generation’: comment from
22 Tanratana et al. *J Thromb Haemost*. 2023 Apr;21(4):1059–61.
- 23 22. Nieuwland R, Gardiner C, Dignat-George F, Mullier F, Mackman N, Woodhams B, Thaler J.
24 Toward standardization of assays measuring extracellular vesicle-associated tissue factor activity.
25 *J Thromb Haemost*. 2019 Aug;17(8):1261–4.
- 26 23. Geddings JE, Hisada Y, Boulaftali Y, Getz TM, Whelihan M, Fuentes R, Dee R, Cooley BC, Key
27 NS, Wolberg AS, Bergmeier W, Mackman N. Tissue factor-positive tumor microvesicles activate
28 platelets and enhance thrombosis in mice. *J Thromb Haemost*. 2016 Jan;14(1):153–66.
- 29 24. Bom VJ, Bertina RM. The contributions of Ca²⁺, phospholipids and tissue-factor apoprotein to
30 the activation of human blood-coagulation factor X by activated factor VII. *Biochem J*. 1990 Jan
31 15;265(2):327–36.
- 32 25. Highton PJ, Goltz FR, Martin N, Stensel DJ, Thackray AE, Bishop NC. Microparticle Responses
33 to Aerobic Exercise and Meal Consumption in Healthy Men. *Med Sci Sports Exerc*. 2019
34 Sep;51(9):1935–43.
- 35 26. Al-Qaissi A, Papageorgiou M, Deshmukh H, Madden LA, Rigby A, Kilpatrick ES, Atkin SL,
36 Sathyapalan T. Effects of acute insulin-induced hypoglycaemia on endothelial microparticles in
37 adults with and without type 2 diabetes. *Diabetes Obes Metab*. 2019 Mar;21(3):533–40.
- 38 27. Chiva-Blanch G, Crespo J, Suades R, Arderiu G, Padro T, Vilahur G, Cubedo J, Corella D, Salas-
39 Salvadó J, Arós F, Martínez-González MA, Ros E, Fitó M, Estruch R, Badimon L.
40 CD142+/CD61+, CD146+ and CD45+ microparticles predict cardiovascular events in high risk
41 patients following a Mediterranean diet supplemented with nuts. *Thromb Haemost*. 2016
42 04;116(1):103–14.

28. Enjeti AK, Ariyarajah A, D'Crus A, Seldon M, Lincz LF. Circulating microvesicle number, function and small RNA content vary with age, gender, smoking status, lipid and hormone profiles. *Thrombosis Research*. 2017 Aug;156:65–72.
29. Mege D, Crescence L, Ouaisi M, Sielezneff I, Guieu R, Dignat-George F, Dubois C, Panicot-Dubois L. Fibrin-bearing microparticles: marker of thrombo-embolic events in pancreatic and colorectal cancers. *Oncotarget*. 2017 Nov 14;8(57):97394–406.
30. Welsh JA, Van Der Pol E, Arkesteijn GJA, Bremer M, Brisson A, Coumans F, Dignat-George F, Duggan E, Ghiran I, Giebel B, Görgens A, Hendrix A, Lacroix R, Lannigan J, Libregts SFWM, Lozano-Andrés E, Morales-Kastresana A, Robert S, De Rond L, Tertel T, Tigges J, De Wever O, Yan X, Nieuwland R, Wauben MHM, Nolan JP, Jones JC. MIFlowCyt-EV: a framework for standardized reporting of extracellular vesicle flow cytometry experiments. *J Extracell Vesicles*. 2020;9(1):1713526.
31. Welsh JA, Arkesteijn GJA, Bremer M, Cimorelli M, Dignat-George F, Giebel B, Görgens A, Hendrix A, Kuiper M, Lacroix R, Lannigan J, van Leeuwen TG, Lozano-Andrés E, Rao S, Robert S, de Rond L, Tang VA, Tertel T, Yan X, Wauben MHM, Nolan JP, Jones JC, Nieuwland R, van der Pol E. A compendium of single extracellular vesicle flow cytometry. *J Extracell Vesicles*. 2023 Feb;12(2):e12299.
32. Campello E, Spiezia L, Radu CM, Bulato C, Castelli M, Gavasso S, Simioni P. Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. *Thromb Res*. 2011 May;127(5):473–7.
33. Y C, J L, Y S, H Z, Y Z, M W, S L, X C, W Z, L L, J W. Annexin V- and tissue factor+ microparticles as biomarkers for predicting deep vein thrombosis in patients after joint arthroplasty. *Clinica chimica acta; international journal of clinical chemistry* [Internet]. 2022 Jan 11 [cited 2023 Mar 28];536. Available from: <https://pubmed.ncbi.nlm.nih.gov/36191610/>
34. Magonette A, Chatelain M, Chatelain B, Ten Cate H, Mullier F. Pre-analytical issues in the haemostasis laboratory: guidance for the clinical laboratories. *Thrombosis J*. 2016 Dec 12;14(1):49.
35. Cvjetkovic A, Lötvall J, Lässer C. The influence of rotor type and centrifugation time on the yield and purity of extracellular vesicles. *J Extracell Vesicles*. 2014;3.
36. Franco C, Lacroix R, Vallier L, Judicone C, Bouriche T, Laroumagne S, Astoul P, Dignat-George F, Poncelet P. A new hybrid immunocapture bioassay with improved reproducibility to measure tissue factor-dependent procoagulant activity of microvesicles from body fluids. *Thromb Res*. 2020 Dec;196:414–24.
36. Featherby S, Madkhali Y, Maraveyas A, Ettelaie C. Apixaban Suppresses the Release of TF-Positive Microvesicles and Restrains Cancer Cell Proliferation through Directly Inhibiting TF-fVIIa Activity. *Thromb Haemost*. 2019;119:1419-1432.
37. Kristensen SR, Nybo J. A sensitive tissue factor activity assay determined by an optimized thrombin generation method. *PLoS One*. 2023;18:e0288918.
38. Ettelaie C, Su S, Li C, Collier ME. Tissue factor-containing microparticles released from mesangial cells in response to high glucose and AGE induce tube formation in microvascular cells. *Microvasc Res*. 2008;76:152-60.
39. Berckmans RJ, Sturk A, van Tienen LM, Schaap MC, Nieuwland R. Cell-derived vesicles exposing coagulant tissue factor in saliva. *Blood*. 2011;117:3172-80.

Figure legends

Figure 1: Evaluation of the specificity of the assays

Samples used to assess the specificity of the assays included two pairs of samples: low EV-TF/low EV-TFKO and high EV-TF/high EV-TFKO.

(A, C) Absolute values of low EV-TF (filled dot) and low EV-TFKO (empty dot). (B, D) Absolute values of high EV-TF (filled dot) and high EV-TFKO (empty dot). (A, B) Evaluation of the specificity of the functional assays. For functional assay 18, this investigator did not measure activity in the low EV-TF sample. (C, D) Evaluation of the specificity of the flow cytometry assays.

Data from assays number 2, 5, 7, 9 and 16 contain extrapolated values (2: high and low EV-TF; 5: low EV-TF; 7: high and low EV-TF; 9: low EV-TF and 16: high and low EV-TF). These data contain values lower than the lowest calibration point.

Abbreviation: Ab: antibody; FCM: flow cytometry; MFI: mean fluorescence intensity; TF: tissue factor; U: unit

Legend: Red dots: FXa generation assays; blue dots: thrombin generation assays; green dots: fibrin generation assays; white and black dots: flow cytometry assays.

* Ratio could not be determined because the denominator was equal to zero.

** Ratio could not be determined because one of the samples was not analyzed.

\$ Outlier. ROUT test ($q=1$) was used to determine outliers.

Figure 2: Evaluation of assay sensitivity

Samples used to assess the sensitivity of the assays included high and low levels of milk-EV, high and low levels of EV-TF, and platelet-depleted plasma from whole blood with or without LPS. Three ratios were calculated between high and low milk-EV, high and low EV-TF, and LPS+/LPS- samples to assess the sensitivity of the assays.

(A, D) Absolute values of high milk-TF (filled dot) and low milk-EV (empty dot). (B, E) Absolute values of high EV-TF (filled dot) and low EV-TF (empty dot). (C, F) Absolute values of LPS+ (filled dot) and LPS- (empty dot) samples. (A-C) Results for functional assays. (D-F) Results for flow cytometry assays.

Data from assays number 2, 5, 7, 8, 9 and 16 contain extrapolated values (2: high and low milk-EV, high and low EV-TF, LPS+; 5: high and low milk-EV, low EV-TF; 7: high and low milk-EV, high and low EV-TF, LPS+; 8: high and low milk-EV, low EV-TF, LPS+; 9: high and low milk-EV, low EV-TF, LPS+; 16: high and low milk-EV, high and low EV-TF, LPS+). These data contain values lower than the lowest calibration point.

Abbreviation: Ab: antibody; FCM: flow cytometry; LPS: lipopolysaccharide; MFI: mean fluorescence intensity; TF: tissue factor; U: unit

Legend: Red dots: FXa generation assays; blue dots: thrombin generation assays; green dots: fibrin generation assays; white and black dots: flow cytometry assays.

Figure 3: Evaluation of the repeatability of the assays

The mean and SD values for each sample and for each assay were obtained from the values of the measurements carried out on the 3 aliquots provided for each sample. All measurements were performed on the same day. (A) Intra-assay variability of the functional assays. (B) Intra-assay variability of the flow cytometry assays. The dashed lines indicate the median for the functional and flow cytometry assays.

Data from assays number 2, 5, 7, 8, 9 and 16 contain extrapolated values (2: high and low milk-EV, high and low EV-TF, LPS+; 5: high and low milk-EV, low EV-TF; 7: high and low milk-EV, high and low EV-TF, LPS+; 8: high and low milk-EV, low EV-TF, LPS+; 9: high and low milk-EV, low EV-TF, LPS+; 16: high and low milk-EV, high and low EV-TF, LPS+). These data contain values lower than the lowest calibration point.

Abbreviations: Ab: antibody; CV: coefficient of variation; FCM: flow cytometry

Legend: Red symbols: FXa generation assays; blue symbols: thrombin generation assays; green symbols: fibrin generation assays; white and black symbols: flow cytometry assays; filled dots: CV high EV-TF; empty dots: CV low EV-TF; filled squares: CV high milk-EV; empty squares: CV low milk-EV; filled triangle: CV LPS+ sample; dotted line: median CV; *: functional assays that used immunocapture to capture TF-positive EVs.

Figure 4: Inter-assay reproducibility

Mean values of the triplicate and respective coefficients of variation (CVs) from 6 specific and sensitive individual functional assays (assays 2, 3, 4, 6, 15 and 18) for 5 samples (high and low milk-EV, high and low EV-TF, and PDP from LPS-stimulated whole blood). Each dot represents the mean value of the activities obtained with one assay. Abbreviations: EV: extracellular vesicle; TF: tissue factor.

Supplemental Figure 1: Samples used for the study

(A) Core lab 1: EV-free plasma supplemented with EV-TF from the parental HAP-1 cell line or EV-TFKO from the HAP-1 knockout TF cell line. (B) Core lab 2: EV-free plasma supplemented with EVs derived from human milk at 2 distinct concentrations. (C) Core lab 3: Platelet-depleted plasma prepared from whole blood with or without LPS stimulation.

Supplemental Figure 2: Analysis of the tissue factor calibrant

Tissue factor (TF) calibrant and Innovin (recombinant tissue factor) were detected by western blotting. The position of tissue factor is shown (rTF). The large band marked with an arrowhead is bovine serum albumin, which is used as a carrier.

Supplemental Figure 3: Characterization of HAP-1 cell lines and EV-TFKO

(A) Relative expression of TF mRNA by RT-qPCR in the 2 cell lines HAP-1 wild-type and HAP-1 TFKO. (B) TF protein expression of HAP-1 wild-type and HAP-1 TFKO cell lines by western blotting. (C) TF protein expression in EV derived from wild-type or TFKO HAP-1 cells by western blotting. (D) TF activity of HAP-1 wild-type and HAP-1 TFKO cell lines measured using a FXa generation assay.

Supplemental Figure 4: Variability of high and low milk-EV triplicate measurement by antigenic assays

Each dot represents one value of the triplicate obtain for high and low milk-EV samples for each antigen assay.

